AI Article Synopsis

  • The case study discusses the use of extracorporeal membrane oxygenation (ECMO) in a 30-year-old woman with septic shock from an invasive pneumococcal infection, highlighting uncertainties around its effectiveness, particularly with hybrid ECMO.
  • After experiencing severe hypoxia and circulatory failure due to septic cardiomyopathy, the patient was initiated on V-V ECMO and later transitioned to V-VA ECMO for enhanced circulatory support.
  • The patient ultimately recovered after extensive treatment, illustrating the potential of timely ECMO transitions to improve outcomes in those with severe respiratory failure linked to septic cardiomyopathy.

Article Abstract

The efficacy of extracorporeal membrane oxygenation (ECMO) for circulatory support in septic shock, especially hybrid ECMO, remains uncertain. A 30-year-old woman presented with septic shock caused by invasive pneumococcal infection, requiring intensive care unit (ICU) admission. Despite maximal respiratory support, her condition worsened with a partial pressure of oxygen (PaO)/fraction of inspired oxygen (FiO) ratio < 60 (The ratio is an indicator of respiratory oxygenation), indicating severe hypoxia and requiring the initiation of veno-venous (V-V) ECMO within three hours. Progressive circulatory failure followed, marked by reduced cardiac function indicative of septic cardiomyopathy; septic cardiomyopathy is a reversible myocardial dysfunction that occurs in patients with sepsis. Transition to veno-venoarterial (V-VA) ECMO took place 13 hours after admission. Liberation from veno-arterial (V-A) ECMO on day 9 and V-V ECMO on day 16 paralleled improvements in circulatory and respiratory functions. Necrosis of both lower extremities, pneumonia and bloodstream infection caused by , prolonged ICU stay until discharge on day 52. Weaned off the ventilator, and with fully recovered consciousness and cardiac function, she was transferred to a rehabilitation facility on day 89. At follow-up more than six months after disease onset, she was doing well and continuing rehabilitation. This case enhances our understanding that when septic cardiomyopathy causes circulatory failure early in the treatment of septic shock, ECMO can serve as life-saving circulatory support. Additionally, the successful use of V-VA ECMO in this case highlights its potential as a therapeutic strategy for patients with severe respiratory failure complicated by septic cardiomyopathy, especially those initially managed with V-V ECMO. Timely transition to V-VA ECMO may improve outcomes in septic patients receiving V-V ECMO when cardiac dysfunction worsens due to septic cardiomyopathy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521961PMC
http://dx.doi.org/10.7759/cureus.70463DOI Listing

Publication Analysis

Top Keywords

septic cardiomyopathy
24
v-v ecmo
16
septic shock
12
v-va ecmo
12
ecmo
11
septic
10
extracorporeal membrane
8
membrane oxygenation
8
caused invasive
8
invasive pneumococcal
8

Similar Publications

Esmolol has been demonstrated to mitigate inflammation damage and T lymphocyte apoptosis in septic cardiomyopathy. It has been established that the activation of α7 nicotinic acetylcholine receptor (nAChR) by cluster of differentiation 4(CD4) T lymphocytes expressing choline acetyltransferase (ChAT) can prevent excessive inflammation and reduce splenocyte apoptosis in septic cardiomyopathy. Given the similar anti-inflammatory effects, we hypothesized that esmolol might be associated with α7 nAChR and thereby exert its cardioprotective functions.

View Article and Find Full Text PDF

A murine model of acute and prolonged abdominal sepsis, supported by intensive care, reveals time-dependent metabolic alterations in the heart.

Intensive Care Med Exp

January 2025

Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Herestraat 49, O&N1 Box 503, 3000, Louvain, Belgium.

Background: Sepsis-induced cardiomyopathy (SICM) often occurs in the acute phase of sepsis and is associated with increased mortality due to cardiac dysfunction. The pathogenesis remains poorly understood, and no specific treatments are available. Although SICM is considered reversible, emerging evidence suggests potential long-term sequelae.

View Article and Find Full Text PDF

Background: High levels of catecholamines are cardiotoxic and associated with stress-induced cardiomyopathies. Septic patients are routinely exposed to endogenously released and exogenously administered catecholamines, which may alter cardiac function and perfusion causing ischemia. Early during human septic shock, left ventricular ejection fraction (LVEF) decreases but normalizes in survivors over 7-10 days.

View Article and Find Full Text PDF

Sepsis-induced cardiomyopathy (SICM) is a life-threatening complication of sepsis characterized by myocardial dysfunction. SICM significantly increases mortality rates in sepsis. Despite its clinical relevance, SICM lacks a unified definition and standardized diagnostic criteria, complicating early identification and treatment.

View Article and Find Full Text PDF

Sepsis often leads to vasoplegia and a hyperdynamic cardiac state, with treatment focused on restoring vascular tone. However, sepsis can also cause reversible myocardial dysfunction, particularly in the elderly with pre-existing heart conditions. The Surviving Sepsis Campaign Guidelines recommend using dobutamine with norepinephrine or epinephrine alone for patients with septic shock with cardiac dysfunction and persistent hypoperfusion despite adequate fluid resuscitation and stable blood pressure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!